BrukerBRKR
BRKR
About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Employees: 11,396
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 122
2.6% more ownership
Funds ownership: 79.43% [Q1] → 82.03% (+2.6%) [Q2]
2% more capital invested
Capital invested by funds: $5.03B [Q1] → $5.12B (+$92.3M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
8% less funds holding
Funds holding: 396 [Q1] → 363 (-33) [Q2]
34% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 80
67% less call options, than puts
Call options by funds: $11M | Put options by funds: $33.2M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
11%
upside
Avg. target
$47
37%
upside
High target
$60
76%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Wells Fargo Brandon Couillard | 47%upside $50 | Overweight Maintained | 5 Aug 2025 |
Stifel Daniel Arias | 17%upside $40 | Hold Maintained | 5 Aug 2025 |
Citigroup Patrick Donnelly | 11%upside $38 | Neutral Maintained | 4 Aug 2025 |
Barclays Luke Sergott | 26%upside $43 | Overweight Maintained | 4 Aug 2025 |
Jefferies Brandon Couillard | 76%upside $60 | Buy Maintained | 4 Aug 2025 |
Financial journalist opinion
Based on 13 articles about BRKR published over the past 30 days
Neutral
Finbold
1 week ago
‘Big Short' Michael Burry stock portfolio update
Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.
Positive
Seeking Alpha
1 week ago
Bruker: Former Academia Customer Strength, Now Incredible Weakness
Bruker faces significant headwinds due to NIH funding cuts, heavy reliance on academia, and declining financial performance versus peers. Despite operational challenges and a sharp drop in valuation, Bruker's NMR technology moat and long-term potential remain intact. I'm accumulating shares gradually at these low valuations, confident in mean reversion and management's ability to consolidate acquisitions.
Neutral
Business Wire
2 weeks ago
Bruker Announces Quarterly Dividend
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop.
Negative
Zacks Investment Research
2 weeks ago
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.
Neutral
Zacks Investment Research
2 weeks ago
Unlocking Bruker (BRKR) International Revenues: Trends, Surprises, and Prospects
Explore Bruker's (BRKR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Neutral
Business Wire
2 weeks ago
Bruker Secures Multi-Year Contracts for Explosives and Chemical Trace Detection in Aviation and Defense Sectors
ETTLINGEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the signing of multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year-to-date in 2025, supporting customers in the aviation security and defense industry to enhance threat detection capabilities. The contracts i.
Negative
Benzinga
2 weeks ago
These Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results
Bruker Corporation BRKR reported worse-than-expected second-quarter financial results and cut its FY25 guidance on Monday.
Negative
Benzinga
3 weeks ago
Bruker Stock: Caution Warranted Despite Bullish Analyst Calls
Bruker Corporation BRKR is currently in the 17th phase of its 18-phase Adhishthana cycle on the weekly chart and signals point to potential trouble ahead. While several large financial institutions remain bullish, our analysis under the Adhishthana Principles suggests a far more cautious stance.
Neutral
Seeking Alpha
3 weeks ago
Bruker Corporation (BRKR) Q2 2025 Earnings Call Transcript
Bruker Corporation (NASDAQ:BRKR ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Frank H. Laukien - Chairman, CEO & President Gerald N.
Positive
Zacks Investment Research
3 weeks ago
Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charts implemented using Lightweight Charts™